دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Aims+Scope/Editorial Board/Publication information
doi : 10.1016/j.radonc.2023.109753
Volume 184, July 2023, 109753
Are hybrid conferences the new standard?
Michael Baumann a,?, Carol Bacchus a , Marianne C. Aznar b , Rob P. Coppes c , Eric Deutsch d , Dietmar Georg e , Karin Haustermans f , Peter Hoskin g , Mechthild Krause h,i , Eric F. Lartigau j , Anne W.M. Lee k , Steffen L?ck i , Birgitte V. Offersen l , Jens Overgaard l , David I. Thwaites m,n , Albert J. van der Kogel o , Uulke A. van der Heide p , Vincenzo Valentini
doi : 10.1016/j.radonc.2023.109695
Volume 184, July 2023, 109695
A perspective on in person scientific meetings
Shilo Lefresne a,b,c,?, Maura Brown b,c,d , Susan Ellard b,c,e , Graeme Duncan c , Jim Rose b,c,f , Michael Darud c,g , Julianna Caon b,c,h , Chad Lund b,c,i , Caroline Mariano
doi : 10.1016/j.radonc.2023.109691
Volume 184, July 2023, 109691
Ferroptosis, necroptosis, and pyroptosis in cancer: Crucial cell death types in radiotherapy and post-radiotherapy immune activation
Youke Wang a,b,c,1 , Yali Wang b,1 , Jing Pan a , Lu Gan d , Jianxin Xue
doi : 10.1016/j.radonc.2023.109689
Volume 184, July 2023, 109689
Prognostic and predictive values of baseline and mid-treatment FDG-PET in oropharyngeal carcinoma treated with primary definitive (chemo)radiation and impact of HPV status: Review of current literature and emerging roles
Peter Lin a,b,c,?, Lois Holloway b,c,f,g , Myo Min d,e , Mark Lee b,f , Allan Fowler
doi : 10.1016/j.radonc.2023.109686
Volume 184, July 2023, 109686
High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: A systematic review and meta-analysis
Yuanhu Yao a,1,?, Jiaying Lu a,b,1 , Zhaohui Qin a,c,1 , Na Li d , Ji Ma b , Nan Yao b , Wanxi Qu b , Li Cui b , Shiwang Yuan b , Aijun Jiang b , Xiaoxiao Liu
doi : 10.1016/j.radonc.2023.109700
Volume 184, July 2023, 109700
No survival benefit with early incorporation of thoracic radiotherapy using daily fractionation in patients with limited-stage small cell lung cancer undergoing chemoradiotherapy in the modern era: A systematic review and meta-analysis
Byoung Hyuck Kim a,b,e , Changhoon Song b,c , Hak Jae Kim b,d,e,
doi : 10.1016/j.radonc.2023.109696
Volume 184, July 2023, 109696
ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma
Maximilian Niyazi a,b,c,?, Nicolaus Andratschke d , Martin Bendszus e , Anthony J Chalmers f , Sara C Erridge g , Norbert Galldiks h,i,j , Frank J Lagerwaard k , Pierina Navarria l , Per Munck af Rosensch?ld m , Umberto Ricardi n , Martin J van den Bent o , Michael Weller p , Claus Belka a,b,c , Giuseppe Minniti
doi : 10.1016/j.radonc.2023.109663
Volume 184, July 2023, 109663
Target delineation in glioblastoma is still a matter of extensive research and debate. This guideline aims to update the existing joint European consensus on delineation of the clinical target volume (CTV) in adult glioblastoma patients.
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023☆
In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with cervical cancer.
doi : 10.1016/j.radonc.2023.109682
Volume 184, July 2023, 109682
In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with cervical cancer.
Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial
Wensi Zhao a , Shaobo Ke a , Xiaojun Cai b , Zhigang Zuo b , Wei Shi a , Hu Qiu a , Gaoke Cai a , Yi Gong a , Yong Wu a , Shasha Ruan a , Yongshun Chen
doi : 10.1016/j.radonc.2023.109679
Volume 184, July 2023, 109679
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study
Ping Peng a,1 , Juejun Gong a,b,1 , Yujie Zhang a,1 , Shuchang Zhou c , Yichen Li a , Guang Han d , Rui Meng e , Yongshun Chen f , Ming Yang g , Qian Shen a , Qian Chu a , Shu Xia a , Peng Zhang a , Lu Zhang a , Yuan Chen a,?, Li Zhang
doi : 10.1016/j.radonc.2023.109681
Volume 184, July 2023, 109681
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant therapeutic effect in the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. However, the acquired resistance greatly limits the survival benefit of EGFR-TKIs for EGFR-mutant NSCLC patients. We aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus EGFR-TKIs in these patients.
Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients
Jing Feng Zong a,b,1 , Po-Ju Lin c,1 , Hsiao-Hui Tsou d,e , Qiaojuan Guo a,b , Yi-Chun Liu f,g , Hanchuan Xu a,b , Chih-Wen Twu h,i , Wei Zheng a,b , Rong-San Jiang j , Kai-Li Liang j , Tian-Yun Lin j , Jian Ji Pan a,b , Shao Jun Lin a,b,?, Jin-Ching Lin
doi : 10.1016/j.radonc.2023.109699
Volume 184, July 2023, 109699
To compare the acute toxicity of two different induction chemotherapy (IndCT) regimen followed by the same IMRT in patients with advanced nasopharyngeal carcinoma (NPC).
Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: Pooled analysis of TRYPHAENA and NeoSphere trials
Omran Saifi a , Bachir Bachir b , Joseph Panoff c , Philip Poortmans d,e , Youssef H. Zeidan
doi : 10.1016/j.radonc.2023.109668
Volume 184, July 2023, 109668
Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma
Jaap P.M. Jaspers a,d,?, Walter Taal b , Yvette van Norden a , Jaap D. Zindler c,d , Annemarie T. Swaak a , Steven J.M. Habraken a,d , Mischa S. Hoogeman a,d , Remi Nout a , Martin J. van den Bent b , Alejandra Méndèz Romero
doi : 10.1016/j.radonc.2023.109674
Volume 184, July 2023, 109674
The interpretation of new enhancing lesions after radiotherapy for diffuse glioma remains a clinical challenge. We sought to characterize and classify new contrast enhancing lesions in a historical multicenter cohort of patients with IDH mutated grade 2 diffuse glioma treated with photon therapy.
Pre-operative stereotactic radiosurgery for cerebral metastatic disease: A retrospective dose-volume study
Alejandro Bugarini a , Evan Meekins b , Joshua Salazar c , Andrea L. Berger d , Michel Lacroix a , Edward A. Monaco III a , Andrew R. Conger a , Anand Mahadevan
doi : 10.1016/j.radonc.2022.07.019
Volume 184, July 2023, 109314
Stereotactic radiosurgery (SRS) after maximal safe resection is an accepted treatment strategy for patients with cerebral metastatic disease. Despite its high conformality profile, the incidence of radionecrosis (RN) remains high. SRS delivered pre-operatively could be associated with a reduced incidence of RN. We sought to evaluate whether neoadjuvant SRS could reduce radiotherapy doses in a cohort of patients treated with post-operative SRS.
CEST imaging of the APT and ssMT predict the overall survival of patients with glioma at the first follow-up after completion of radiotherapy at 3T
Nikolaus von Knebel Doeberitz a , Florian Kroh b,g , Johannes Breitling b , Laila K?nig c , Srdjan Maksimovic a , Svenja Gra? a , Sebastian Adeberg c,i , Moritz Scherer d , Andreas Unterberg d,i , Martin Bendszus e,i , Wolfgang Wick f,i , Peter Bachert b,g , Jürgen Debus c,h,i , Mark E. Ladd b,g,i , Heinz-Peter Schlemmer a,i , Andreas Korzowski b , Steffen Goerke b , Daniel Paech
doi : 10.1016/j.radonc.2023.109694
Volume 184, July 2023, 109694
Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model based clinic
Bas A. de Jong a,?, Erik W. Korevaar a , Anneke Maring a , Chimène I. Werkman a , Daniel Scandurra a , Guillaume Janssens b , Stefan Both a , Johannes A. Langendijk
doi : 10.1016/j.radonc.2023.109670
Volume 184, July 2023, 109670
Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients
Da-wei Zhao a,b,c,1 , Feng Teng d,1 , Ling-ling Meng b,e,1 , Wen-jun Fan b,f,g , Yan-rong Luo b , Hua-yong Jiang b,e , Nan-xiang Chen h , Xin-xin Zhang h , Wei Yu b,e , Bo-ning Cai b,e , Lu-jun Zhao a,?, Pei-guo Wang a,?, Lin Ma
doi : 10.1016/j.radonc.2023.109683
Volume 184, July 2023, 109683
Aim to create and validate a comprehensive nomogram capable of accurately predicting the transition from moderate-severe to normal-mild xerostomia post-radiotherapy (postRT) in patients with nasopharyngeal carcinoma (NPC).
A pulmonary vein atlas for radiotherapy planning
Gerard M Walls a,b,?, Conor McCann c , Peter Ball d , Katelyn M Atkins e , Raymond H Mak f , Ahmed Bedair g , Jolyne O’Hare a , Jonathan McAleese a , Claire Harrison a , Karen A Tumelty a , Cathryn Crockett a , Sarah-Louise Black a , Catherine Nelson a , John O’Connor b , Alan R Hounsell a,b , Conor K McGarry a,b , Karl T Butterworth b , Aidan J Cole a,b , Suneil Jain a,b,1 , Gerard G Hanna a
doi : 10.1016/j.radonc.2023.109680
Volume 184, July 2023, 109680
Cardiac arrhythmia is a recognised potential complication of thoracic radiotherapy, but the responsible cardiac substructures for arrhythmogenesis have not been identified. Arrhythmogenic tissue is commonly located in the pulmonary veins (PVs) of cardiology patients with arrhythmia, however these structures are not currently considered organs-at-risk during radiotherapy planning. A standardised approach to their delineation was developed and evaluated.
The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients
Cem Onal a,b,?, Gurcan Erbay c , Ezgi Oymak d , Ozan Cem Guler
doi : 10.1016/j.radonc.2023.109677
Volume 184, July 2023, 109677
We assessed early changes in apparent diffusion coefficient (ADC) and serum prostate specific antigen (PSA) values after definitive radiotherapy (RT) without androgen deprivation treatment in low- and intermediate-risk prostate cancer (PC) patients.
Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study
Mark T. Corkum a,?, Mark K. Buyyounouski b , Albert J. Chang c , Hans T. Chung d , Peter Chung e , Brett W. Cox f , Juanita M. Crook g , Brian J. Davis h , Steven J. Frank i , Ivan Henriquez j , Eric M. Horwitz k , Peter Hoskin l , I-Chow Hsu m , Mira Keyes n , Martin T. King o , Marisa A. Kollmeier p , Daniel J. Krauss q , Andrzej M. Kukielka r,s , Gerard Morton d , Peter F. Orio III o , Bradley R. Pieters t,u , Louis Potters v , Peter J. Rossi w , Timothy N. Showalter x , Abhishek A. Solanki y , Daniel Song z , Ben Vanneste aa , Eric Vigneault ab , Piotr A. Wojcieszek ac , Michael J. Zelefsky p , Mitchell Kamrava
doi : 10.1016/j.radonc.2023.109672
Volume 184, July 2023, 109672
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study
Sophia Scharl a,?, Constantinos Zamboglou b,c,d,e , Iosif Strouthos f , Andrea Farolfi g , Francesca Serani g , Helena Lanzafame g,v , Alessio Giuseppe Morganti h , Christian Trapp i , Stefan A. Koerber j,k , Jürgen Debus j,k , Jan C. Peeken l,m,n , Marco M.E. Vogel l,m,n , Alexis Vrachimis o,p , Simon K.B. Spohn b,c,d , Juri Ruf c,q , Anca-Ligia Grosu b,c , Francesco Ceci r , Wolfgang P. Fendler s,t , Peter Bartenstein u , Stephanie G.C. Kroeze w,ad , Matthias Guckenberger w , Manuel Krafcsik a , Christina Klopscheck af , Stefano Fanti g , George Hruby v , Louise Emmett x,y , Claus Belka i , Christian Stief z , Nina-Sophie Schmidt-Hegemann i , Christoph Henkenberens aa , Benjamin Mayer ab , Jonathan Miksch ac , Mohamed Shelan ae , Daniel M. Aebersold ae , Reinhard Thamm a , Thomas Wiegel
doi : 10.1016/j.radonc.2023.109678
Volume 184, July 2023, 109678
Repeat stereotactic body radiotherapy for oligometastatic disease
Jonas Willmann a,b,1 , Selma Adilovic a,1 , Eugenia Vlaskou Badra a , Sebastian M. Christ a , Maiwand Ahmadsei a , Stephanie Tanadini-Lang a , Michael Mayinger a , Matthias Guckenberger a , Nicolaus Andratschke
doi : 10.1016/j.radonc.2023.109671
Volume 184, July 2023, 109671
Patients with oligometastatic disease (OMD) treated with metastasis-directed definitive local therapy such as stereotactic body radiotherapy (SBRT) are at risk of developing new metastases. Here, we compare characteristics and outcomes of patients treated with a single course and repeat SBRT.
The use of in-vivo dosimetry to identify head and neck cancer patients needing adaptive radiotherapy
Yawo A.C. Fiagan a,b,?, Evy Bossuyt a , Daan Nevens a,c , Melanie Machiels a,c , Ibrahim Chiairi a,c , Ines Joye a,c , Paul Meijnders a,c , Thierry Gevaert b,d , Dirk Verellen
doi : 10.1016/j.radonc.2023.109676
Volume 184, July 2023, 109676
Head and neck cancer (HNC) patients experiencing anatomical changes during their radiotherapy (RT) course may benefit from adaptive RT (ART). We investigated the sensitivity of an electronic portal imaging device (EPID)-based in-vivo dosimetry (EIVD) system to detect patients that require ART and identified its limitations.
Consensus guide on CT-based prediction of stopping-power ratio using a Hounsfield look-up table for proton therapy
Nils Peters a,b,1,?, Vicki Trier Taasti c,1,?, Benjamin Ackermann d,2 , Alessandra Bolsi e,2 , Christina Vallhagen Dahlgren f,2 , Malte Ellerbrock d,2 , Francesco Fracchiolla g,2 , Carles Gomà h,2 , Joanna G?ra i,2 , Patricia Cambraia Lopes j,2 , Ilaria Rinaldi c,2 , Koen Salvo k,2 , Ivanka Sojat Tarp l,2 , Alessandro Vai m,2 , Thomas Bortfeld b , Antony Lomax e , Christian Richter a,n,o,p , Patrick Wohlfahrt
doi : 10.1016/j.radonc.2023.109675
Volume 184, July 2023, 109675
Studies have shown large variations in stopping-power ratio (SPR) prediction from computed tomography (CT) across European proton centres. To standardise this process, a step-by-step guide on specifying a Hounsfield look-up table (HLUT) is presented here.
Implementation and evaluation of an intelligent automatic treatment planning robot for prostate cancer stereotactic body radiation therapy
Yin Gao a,b,1 , Chenyang Shen a,b , Xun Jia a,b,?, Yang Kyun Park
doi : 10.1016/j.radonc.2023.109685
Volume 184, July 2023, 109685
We previously developed a virtual treatment planner (VTP), an artificial intelligence robot, operating a treatment planning system (TPS). Using deep reinforcement learning guided by human knowledge, we trained the VTP to autonomously adjust relevant parameters in treatment plan optimization, similar to a human planner, to generate high-quality plans for prostate cancer stereotactic body radiation therapy (SBRT). This study describes the clinical implementation and evaluation of VTP.
Comprehensive dose evaluation of a Deep Learning based synthetic Computed Tomography algorithm for pelvic Magnetic Resonance-only radiotherapy
Jonathan J Wyatt a,b,?, Sandeep Kaushik c,d , Cristina Cozzini c , Rachel A. Pearson a,b , Steven Petit e , Marta Capala e , Juan A Hernandez-Tamames f , Katalin Hideghéty g , Ross J Maxwell a , Florian Wiesinger c , Hazel M. McCallum
doi : 10.1016/j.radonc.2023.109692
Volume 184, July 2023, 109692
Magnetic Resonance (MR)-only radiotherapy enables the use of MR without the uncertainty of MR–Computed Tomography (CT) registration. This requires a synthetic CT (sCT) for dose calculations, which can be facilitated by a novel Zero Echo Time (ZTE) sequence where bones are visible and images are acquired in 65 seconds. This study evaluated the dose calculation accuracy for pelvic sites of a ZTE-based Deep Learning sCT algorithm developed by GE Healthcare.
A subregion-based prediction model for local–regional recurrence risk in head and neck squamous cell carcinoma
Ziqi Pan, Kuo Men, Bin Liang, Zhiyue Song, Runye Wu, Jianrong Dai
doi : 10.1016/j.radonc.2023.109684
Volume 184, July 2023, 109684
Mechanisms of the ‘FLASH’ effect: Radiation chemistry should not be ignored in developing models
Peter Wardman
doi : 10.1016/j.radonc.2023.109673
Volume 184, July 2023, 109673
Corrigendum to “Master protocol trial design for technical feasibility of MR-guided radiotherapy� [Radiother. Oncol. 166 (2022) 33–36]
Alice Couwenberg ?, Uulke Van der Heide, Tomas Janssen, Baukelien Van Triest, Peter Remeijer, Corrie Marijnen, Jan-Jakob Sonke, Marlies Nowee
doi : 10.1016/j.radonc.2023.109693
Volume 184, July 2023, 109693
